Literature DB >> 7557881

Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis.

J F Whiting1, R M Green, A B Rosenbluth, J L Gollan.   

Abstract

Tumor necrosis factor-alpha (TNF alpha), a cytokine that is produced in a variety of inflammatory diseases associated with cholestasis, is believed to be the primary mediator of the systemic effects of endotoxin. Thus, we have investigated the role of TNF alpha in the pathogenesis of endotoxin-induced cholestasis in intact animals, and in the uptake of taurocholate by cultured hepatocytes. Male Sprague-Dawley rats received either intravenous (IV) endotoxin (7.5 mg/kg) or monoclonal anti-TNF alpha antibody followed by endotoxin. Basal bile flow and bile salt excretion were measured for a 2-hour period, after which all animals received an IV bolus of taurocholate (10 mumol/100 g body weight). Endotoxin decreased basal bile flow by 41% and bile salt stimulated bile flow by 38% (n = 12; P < .01). Basal bile salt excretion was decreased 86% after endotoxin administration. Passive immunization with anti-TNF alpha antibody blocked this endotoxin-associated cholestasis. In addition, rat hepatocytes were isolated and cultured in the presence of either endotoxin (10 micrograms/mL) or TNF alpha (100 ng/mL) for 24 hours. These primary hepatocyte cultures exhibited a dose- and time-dependent, noncompetitive, inhibition of taurocholate uptake. We postulate that TNF alpha is an important mediator of the cholestasis of sepsis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557881     DOI: 10.1016/0270-9139(95)90639-8

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  25 in total

1.  Biliary interleukin-6 and tumor necrosis factor-alpha in patients undergoing endoscopic retrograde cholangiopancreatography.

Authors:  H R Rosen; P J Winkle; B J Kendall; D L Diehl
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

2.  Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors.

Authors:  M Trauner; M Arrese; H Lee; J L Boyer; S J Karpen
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

3.  Intrahepatic cholestasis as a paraneoplastic syndrome associated with pheochromocytoma.

Authors:  C H Chung; C H Wang; C Y Tzen; C P Liu
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

4.  Granulocyte colony-stimulating factor enhances endotoxin-induced decrease in biliary excretion of the antibiotic cefoperazone in rats.

Authors:  M Nadai; I Matsuda; L Wang; A Itoh; K Naruhashi; T Nabeshima; M Asai; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  The multiple organ dysfunction syndrome and late-phase mortality in sepsis.

Authors:  Joshua A Englert; Mitchell P Fink
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 6.  Does abnormal bile acid metabolism contribute to NEC?

Authors:  Melissa D Halpern; Bohuslav Dvorak
Journal:  Semin Perinatol       Date:  2008-04       Impact factor: 3.300

7.  Hyperbilirubinemia as a predictive factor in acute appendicitis.

Authors:  T Eren; E Tombalak; I A Ozemir; M Leblebici; S Ziyade; O Ekinci; O Alimoglu
Journal:  Eur J Trauma Emerg Surg       Date:  2015-08-08       Impact factor: 3.693

8.  Influence of modest endotoxemia on postoperative antithrombin deficiency and circulating secretory immunoglobulin a levels.

Authors:  Tetsuji Fujita; Takashi Imai; Sadao Anazawa
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

9.  IL-6 modulates sepsis-induced decreases in transcription of hepatic organic anion and bile acid transporters.

Authors:  Kenneth M Andrejko; Nichelle R Raj; Patrick K Kim; Maurizio Cereda; Clifford S Deutschman
Journal:  Shock       Date:  2008-04       Impact factor: 3.454

Review 10.  Bile formation and secretion.

Authors:  James L Boyer
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.